Lundquist Lisa
Mercer University College of Pharmacy and Health Science, Atlanta, GA 30341, USA.
Adv Ther. 2007 Mar-Apr;24(2):333-45. doi: 10.1007/BF02849902.
An enhanced understanding of the immunopathology of rheumatoid arthritis (RA) has led to the development of novel therapies that target specific events occurring in the immune cascade that underlies the disease. In December 2005, abatacept became the first therapy to be approved by the US Food and Drug Administration for the treatment of adult patients with moderately to severely active RA who have exhibited an inadequate response to traditional disease-modifying antirheumatic drugs or tumor necrosis factor antagonists. This article summarizes the characteristics and clinical profile of abatacept. Abatacept is a fully human soluble recombinant fusion protein that acts by binding to CD80/CD86 on antigen-presenting cells and inhibiting interaction with CD28 on T cells, thus preventing one of the co-stimulatory signals needed for full T-cell activation. It is indicated for reducing signs and symptoms of the disorder, inducing a major clinical response, slowing the progression of structural damage, and improving physical function in this patient population. Data on abatacept compiled to date demonstrate significant efficacy, combined with a consistent safety profile and tolerability, in a wide range of patients with RA, including those with an inadequate response to methotrexate or to tumor necrosis factor antagonists.
对类风湿关节炎（RA）免疫病理学的深入理解促使了针对该疾病免疫级联反应中特定事件的新型疗法的开发。2005年12月，阿巴西普成为首个获美国食品药品监督管理局批准用于治疗对传统抗风湿药物或肿瘤坏死因子拮抗剂反应不足的中度至重度活动性成年RA患者的疗法。本文总结了阿巴西普的特性和临床概况。阿巴西普是一种完全人源化的可溶性重组融合蛋白，其作用机制是与抗原呈递细胞上的CD80/CD86结合，抑制与T细胞上CD28的相互作用，从而阻止T细胞完全激活所需的共刺激信号之一。它适用于减轻该疾病的体征和症状、诱导主要临床反应、减缓结构损伤的进展以及改善该患者群体的身体功能。迄今为止收集的有关阿巴西普的数据表明，在包括对甲氨蝶呤或肿瘤坏死因子拮抗剂反应不足的广泛RA患者中，该药具有显著疗效，同时具有一致的安全性和耐受性。
